{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T02:24:28Z","timestamp":1786933468099,"version":"build-2736575974"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":67,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Haryana State Council for Science, Innovation and Technology, Government of Haryana","award":["HSCSIT\/R&D\/2025\/1558"],"award-info":[{"award-number":["HSCSIT\/R&D\/2025\/1558"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"DOI":"10.1186\/s13063-026-09534-5","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T02:33:53Z","timestamp":1781145233000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of SarogLItazar as an add-on medication to Metformin and lifestyle intervention in women with PolyCystic Ovary Syndrome (SLIM-PCOS trial): study protocol for a randomized, open-label, parallel group clinical trial"],"prefix":"10.1186","volume":"27","author":[{"given":"Niti","family":"Mittal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savita","family":"Singhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Mittal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"key":"9534_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.57","volume":"2","author":"R Azziz","year":"2016","unstructured":"Azziz R, Carmina E, Chen Z, et al. Polycystic ovary syndrome. Nat Rev Dis Primers. 2016;2:16057. https:\/\/doi.org\/10.1038\/nrdp.2016.57.","journal-title":"Nat Rev Dis Primers"},{"key":"9534_CR2","unstructured":"Polycystic ovary syndrome. Available at: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/polycystic-ovary-syndrome"},{"issue":"4","key":"9534_CR3","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1093\/humrep\/deaa371","volume":"36","author":"J Liu","year":"2021","unstructured":"Liu J, Wu Q, Hao Y, et al. Measuring the global disease burden of polycystic ovary syndrome in 194 countries: Global Burden of Disease Study 2017. Hum Reprod. 2021;36(4):1108\u201319. https:\/\/doi.org\/10.1093\/humrep\/deaa371.","journal-title":"Hum Reprod"},{"issue":"10","key":"9534_CR4","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.40583","volume":"7","author":"MA Ganie","year":"2024","unstructured":"Ganie MA, Chowdhury S, Malhotra N, et al. Prevalence, phenotypes, and comorbidities of polycystic ovary syndrome among Indian women. JAMA Netw Open. 2024;7(10):e2440583. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.40583.","journal-title":"JAMA Netw Open"},{"key":"9534_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25169037","volume":"25","author":"KJ Chang","year":"2024","unstructured":"Chang KJ, Chen JH, Chen KH. The pathophysiological mechanism and clinical treatment of polycystic ovary syndrome: a molecular and cellular review of the literature. Int J Mol Sci. 2024;25:9037. https:\/\/doi.org\/10.3390\/ijms25169037.","journal-title":"Int J Mol Sci"},{"key":"9534_CR6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/GRF.0000000000000563","volume":"64","author":"JA Lentscher","year":"2021","unstructured":"Lentscher JA, Decherney AH. Clinical presentation and diagnosis of polycystic ovarian syndrome. Clin Obstet Gynecol. 2021;64:3\u201311. https:\/\/doi.org\/10.1097\/GRF.0000000000000563.","journal-title":"Clin Obstet Gynecol"},{"issue":"6","key":"9534_CR7","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/j.fertnstert.2020.12.018","volume":"115","author":"KJ Ryu","year":"2021","unstructured":"Ryu KJ, Kim MS, Kim HK, et al. Risk of type 2 diabetes is increased in nonobese women with polycystic ovary syndrome: the National Health Insurance Service-National Sample Cohort Study. Fertil Steril. 2021;115(6):1569\u201375. https:\/\/doi.org\/10.1016\/j.fertnstert.2020.12.018.","journal-title":"Fertil Steril"},{"issue":"1","key":"9534_CR8","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1210\/clinem\/dgab658","volume":"107","author":"C Falzarano","year":"2022","unstructured":"Falzarano C, Lofton T, Osei-Ntansah A, et al. Nonalcoholic fatty liver disease in women and girls with polycystic ovary syndrome. J Clin Endocrinol Metab. 2022;107(1):258\u201372. https:\/\/doi.org\/10.1210\/clinem\/dgab658.","journal-title":"J Clin Endocrinol Metab"},{"key":"9534_CR9","doi-asserted-by":"publisher","unstructured":"Karthik S, Vipin VP, Kapoor A, et al. Cardiovascular disease risk in the siblings of women with polycystic ovary syndrome. Hum Reprod. 2019;34(8):1559\u201366. Do i: https:\/\/doi.org\/10.1093\/humrep\/dez104.","DOI":"10.1093\/humrep\/dez104"},{"issue":"1","key":"9534_CR10","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1001\/jamaoncol.2018.5188","volume":"5","author":"W Yin","year":"2019","unstructured":"Yin W, Falconer H, Yin L, et al. Association between polycystic ovary syndrome and cancer risk. JAMA Oncol. 2019;5(1):106\u20137. https:\/\/doi.org\/10.1001\/jamaoncol.2018.5188.","journal-title":"JAMA Oncol"},{"issue":"3","key":"9534_CR11","doi-asserted-by":"publisher","first-page":"129","DOI":"10.4239\/wjd.v13.i3.129","volume":"13","author":"CA Amisi","year":"2022","unstructured":"Amisi CA. Markers of insulin resistance in polycystic ovary syndrome women: an update. World J Diabetes. 2022;13(3):129\u201349. https:\/\/doi.org\/10.4239\/wjd.v13.i3.129.","journal-title":"World J Diabetes"},{"key":"9534_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-021-00710-z","volume":"21","author":"FKH Shirazi","year":"2021","unstructured":"Shirazi FKH, Khodamoradi Z, Jeddi M. Insulin resistance and high molecular weight adiponectin in obese and non-obese patients with polycystic ovarian syndrome (PCOS). BMC Endocr Disord. 2021;21:45. https:\/\/doi.org\/10.1186\/s12902-021-00710-z.","journal-title":"BMC Endocr Disord"},{"key":"9534_CR13","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.fertnstert.2018.09.013","volume":"111","author":"S Zhu","year":"2019","unstructured":"Zhu S, Zhang B, Jiang X, et al. Metabolic disturbances in non-obese women with polycystic ovary syndrome: a systematic review and meta-analysis. Fertil Steril. 2019;111:168\u201377. https:\/\/doi.org\/10.1016\/j.fertnstert.2018.09.013.","journal-title":"Fertil Steril"},{"key":"9534_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2022.102345","volume":"68","author":"KA Glendining","year":"2023","unstructured":"Glendining KA, Campbell RE. Recent advances in emerging PCOS therapies. Curr Opin Pharmacol. 2023;68:102345. https:\/\/doi.org\/10.1016\/j.coph.2022.102345.","journal-title":"Curr Opin Pharmacol"},{"issue":"3","key":"9534_CR15","doi-asserted-by":"publisher","first-page":"e1071","DOI":"10.1210\/clinem\/dgaa839","volume":"106","author":"KM Hoeger","year":"2021","unstructured":"Hoeger KM, Dokras A, Piltonen T. Update on PCOS: consequences, challenges, and guiding treatment. J Clin Endocrinol Metab. 2021;106(3):e1071\u201383. https:\/\/doi.org\/10.1210\/clinem\/dgaa839.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"9534_CR16","doi-asserted-by":"publisher","first-page":"2950","DOI":"10.1210\/clinem\/dgaa337","volume":"105","author":"C Xing","year":"2020","unstructured":"Xing C, Li C, He B. Insulin sensitizers for improving the endocrine and metabolic profile in overweight women with PCOS. J Clin Endocrinol Metab. 2020;105(9):2950\u201363. https:\/\/doi.org\/10.1210\/clinem\/dgaa337.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"9534_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12978-021-01207-7","volume":"18","author":"H Zhao","year":"2021","unstructured":"Zhao H, Xing C, Zhang J, He B. Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis. Reprod Health. 2021;18(1):171. https:\/\/doi.org\/10.1186\/s12978-021-01207-7.","journal-title":"Reprod Health"},{"key":"9534_CR18","doi-asserted-by":"publisher","DOI":"10.1177\/20420188221127142","volume":"13","author":"MA Abdalla","year":"2022","unstructured":"Abdalla MA, Shah N, Deshmukh H, Sahebkar A, \u00d6stlundh L, Al-Rifai RH, et al. Impact of metformin on the clinical and metabolic parameters of women with polycystic ovary syndrome: a systematic review and meta-analysis of randomised controlled trials. Ther Adv Endocrinol Metab. 2022;13:20420188221127142. https:\/\/doi.org\/10.1177\/20420188221127142.","journal-title":"Ther Adv Endocrinol Metab"},{"key":"9534_CR19","doi-asserted-by":"publisher","unstructured":"Morley LC, Tang T, Yasmin E, Norman RJ, Balen AH. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev. 2017 Nov 29;11(11):CD003053. https:\/\/doi.org\/10.1002\/14651858.","DOI":"10.1002\/14651858"},{"key":"9534_CR20","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/5150684","volume":"2020","author":"Y Guan","year":"2020","unstructured":"Guan Y, Wang D, Bu H, Zhao T, Wang H. The effect of metformin on polycystic ovary syndrome in overweight women: a systematic review and meta-analysis of randomized controlled trials. Int J Endocrinol. 2020;2020:5150684. https:\/\/doi.org\/10.1155\/2020\/5150684.","journal-title":"Int J Endocrinol"},{"key":"9534_CR21","doi-asserted-by":"publisher","unstructured":"Heidarpour M, Mojarad M, Mazaheri-Tehrani S, et al. Comparative effectiveness of antidiabetic drugs as an additional therapy to metformin in women with polycystic ovary syndrome: a systematic review of metabolic approaches. Int J Endocrinol. 2024; 9900213. https:\/\/doi.org\/10.1155\/2024\/9900213.","DOI":"10.1155\/2024\/9900213"},{"issue":"1","key":"9534_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s12905-025-03594-6","volume":"25","author":"Y Bo","year":"2025","unstructured":"Bo Y, Zhao J, Liu C, Yu T. Comparative efficacy of pharmacological interventions on metabolic and hormonal outcomes in polycystic ovary syndrome: a network meta-analysis of randomized controlled trials. BMC Womens Health. 2025;25(1):64. https:\/\/doi.org\/10.1186\/s12905-025-03594-6.","journal-title":"BMC Womens Health"},{"issue":"1","key":"9534_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-99622-4","volume":"15","author":"S Lin","year":"2025","unstructured":"Lin S, Deng Y, Huang J, Li M, Sooranna SR, Qin M, et al. Efficacy and safety of GLP-1 receptor agonists on weight management and metabolic parameters in PCOS women: a meta-analysis of randomized controlled trials. Sci Rep. 2025;15(1):16512. https:\/\/doi.org\/10.1038\/s41598-025-99622-4.","journal-title":"Sci Rep"},{"issue":"5","key":"9534_CR24","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1007\/s43032-025-01788-9","volume":"32","author":"Y Zhao","year":"2025","unstructured":"Zhao Y, Jiang L, Li N, Cao J, Pi J. Comparison of GLP-1 receptor agonists combined with metformin versus metformin alone in the management of PCOS: a comprehensive meta-analysis. Reprod Sci. 2025;32(5):1661\u201375. https:\/\/doi.org\/10.1007\/s43032-025-01788-9.","journal-title":"Reprod Sci"},{"key":"9534_CR25","doi-asserted-by":"publisher","unstructured":"Austreg\u00e9silo de Athayde De Hollanda Morais B, Martins Priz\u00e3o V, de Moura de Souza M, Ximenes Mendes B, Rodrigues Defante ML, Cosendey Martins O, Rodrigues AM. The efficacy and safety of GLP-1 agonists in PCOS women living with obesity in promoting weight loss and hormonal regulation: a meta-analysis of randomized controlled trials. J Diabetes Complications. 2024 Oct;38(10):108834. https:\/\/doi.org\/10.1016\/j.jdiacomp.2024.108834.","DOI":"10.1016\/j.jdiacomp.2024.108834"},{"issue":"2","key":"9534_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23020583","volume":"23","author":"HM Sadeghi","year":"2022","unstructured":"Sadeghi HM, Adeli I, Calina D, Docea AO, Mousavi T, Daniali M, et al. Polycystic ovary syndrome: a comprehensive review of pathogenesis, management, and drug repurposing. Int J Mol Sci. 2022;23(2):583. https:\/\/doi.org\/10.3390\/ijms23020583.","journal-title":"Int J Mol Sci"},{"key":"9534_CR27","doi-asserted-by":"publisher","unstructured":"Saadati S, Mason T, Godini R, Vanky E, Teede H, Mousa A. Metformin use in women with polycystic ovary syndrome (PCOS): opportunities, benefits, and clinical challenges. Diabetes Obes Metab. 2025 Jun;27 Suppl 3(Suppl 3):31\u201347. https:\/\/doi.org\/10.1111\/dom.16422.","DOI":"10.1111\/dom.16422"},{"issue":"1","key":"9534_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s13048-024-01367-7","volume":"17","author":"H Zhao","year":"2024","unstructured":"Zhao H, Zhang J, Xing C, Cheng X, He B. Metformin versus metformin plus pioglitazone on gonadal and metabolic profiles in normal weight women with polycystic ovary syndrome: a single-center, open-labeled prospective randomized controlled trial. J Ovarian Res. 2024;17(1):42. https:\/\/doi.org\/10.1186\/s13048-024-01367-7.","journal-title":"J Ovarian Res"},{"issue":"11","key":"9534_CR29","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1055\/a-1018-9606","volume":"51","author":"M Shah","year":"2019","unstructured":"Shah M, Ali A, Malik MO, et al. Treatment with metformin and combination of metformin plus pioglitazone on serum levels of IL-6 and IL-8 in polycystic ovary syndrome: a randomized clinical trial. Horm Metab Res. 2019;51(11):714\u201322. https:\/\/doi.org\/10.1055\/a-1018-9606.","journal-title":"Horm Metab Res"},{"issue":"1","key":"9534_CR30","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.fertnstert.2019.09.011","volume":"113","author":"Y Li","year":"2020","unstructured":"Li Y, Tan J, Wang Q, Duan C, Hu Y, Huang W. Comparing the individual effects of metformin and rosiglitazone and their combination in obese women with polycystic ovary syndrome: a randomized controlled trial. Fertil Steril. 2020;113(1):197\u2013204. https:\/\/doi.org\/10.1016\/j.fertnstert.2019.09.011.","journal-title":"Fertil Steril"},{"issue":"1","key":"9534_CR31","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.fertnstert.2016.09.023","volume":"107","author":"KE Elkind-Hirsch","year":"2017","unstructured":"Elkind-Hirsch KE, Paterson MS, Seidemann EL, Gutowski HC. Short term therapy with combination dipeptidyl peptidase-4 inhibitor saxagliptin\/metformin extended release (XR) is superior to saxagliptin or metformin XR monotherapy in prediabetic women with polycystic ovary syndrome: a single-blind, randomized, pilot study. Fertil Steril. 2017;107(1):253-260.e1. https:\/\/doi.org\/10.1016\/j.fertnstert.2016.09.023.","journal-title":"Fertil Steril"},{"issue":"10","key":"9534_CR32","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1089\/met.2017.0095","volume":"15","author":"S Ferjan","year":"2017","unstructured":"Ferjan S, Janez A, Jensterle M. Dipeptidyl peptidase-4 inhibitor sitagliptin prevented weight regain in obese women with polycystic ovary syndrome previously treated with liraglutide: a pilot randomized study. Metab Syndr Relat Disord. 2017;15(10):515\u201320. https:\/\/doi.org\/10.1089\/met.2017.0095.","journal-title":"Metab Syndr Relat Disord"},{"key":"9534_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.945609","volume":"13","author":"C Xing","year":"2022","unstructured":"Xing C, Zhao H, Zhang J, He B. Effect of metformin versus metformin plus liraglutide on gonadal and metabolic profiles in overweight patients with polycystic ovary syndrome. Front Endocrinol. 2022;13:945609. https:\/\/doi.org\/10.3389\/fendo.2022.945609.","journal-title":"Front Endocrinol"},{"issue":"3","key":"9534_CR34","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1530\/EJE-13-0797","volume":"170","author":"M Jensterle Sever","year":"2014","unstructured":"Jensterle Sever M, Kocjan T, Pfeifer M, Kravos NA, Janez A. Short term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin. Eur J Endocrinol. 2014;170(3):451\u20139. https:\/\/doi.org\/10.1530\/EJE-13-0797.","journal-title":"Eur J Endocrinol"},{"key":"9534_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1156521","volume":"14","author":"Q Wen","year":"2023","unstructured":"Wen Q, Fang S, Liang Y, et al. Short-term effect of beinaglutide combined with metformin versus metformin alone on weight loss and metabolic profiles in obese patients with polycystic ovary syndrome: a pilot randomized trial. Front Endocrinol. 2023;14:1156521. https:\/\/doi.org\/10.3389\/fendo.2023.1156521.","journal-title":"Front Endocrinol"},{"issue":"23","key":"9534_CR36","doi-asserted-by":"publisher","first-page":"2882","DOI":"10.1097\/CM9.0000000000001712","volume":"134","author":"R-L Ma","year":"2021","unstructured":"Ma R-L, Deng Y, Wang Y-F, Zhu S-Y, Ding X-S, Sun A-J. Short-term combined treatment with exenatide and metformin for overweight\/obese women with polycystic ovary syndrome. Chin Med J (Engl). 2021;134(23):2882\u20139. https:\/\/doi.org\/10.1097\/CM9.0000000000001712.","journal-title":"Chin Med J (Engl)"},{"issue":"7","key":"9534_CR37","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1210\/jc.2008-0115","volume":"93","author":"K Elkind-Hirsch","year":"2008","unstructured":"Elkind-Hirsch K, Marrioneaux O, Bhushan M, Vernor D, Bhushan R. Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2008;93(7):2670\u20138. https:\/\/doi.org\/10.1210\/jc.2008-0115.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"9534_CR38","volume":"6","author":"G Nirmala","year":"2022","unstructured":"Nirmala G, Sannappa G, Varsha DS, et al. Therapeutic role of saroglitazar in NAFLD and metabolic syndrome. Nov Appro Drug Des Dev. 2022;6(3):555689.","journal-title":"Nov Appro Drug Des Dev"},{"key":"9534_CR39","unstructured":"List of new drugs approved in the year 2020 till date. Downloaded from https:\/\/cdsco.gov.in\/opencms\/opencms\/en\/Approval_new\/Approved-New-Drugs\/"},{"key":"9534_CR40","unstructured":"List of new drugs approved 2013. Downloaded from https:\/\/cdsco.gov.in\/opencms\/opencms\/en\/Approval_new\/Approved-New-Drugs\/"},{"key":"9534_CR41","unstructured":"Saroglitazar magnesium 4 mg in the treatment of NAFLD in women with PCOS (EVIDENCES VII). https:\/\/ichgcp.net\/clinical-trials-registry\/NCT03617263 (Accessed on 11.11.2024)."},{"key":"9534_CR42","doi-asserted-by":"publisher","unstructured":"Chan A-W, Boutron I, Hopewell S, Moher D, Schulz KF, et al. SPIRIT 2025 statement: updated guideline for protocols of randomised trials. BMJ 025;389:e081477.https:\/\/doi.org\/10.1136\/bmj-2024-081477","DOI":"10.1136\/bmj-2024-081477"},{"issue":"1","key":"9534_CR43","doi-asserted-by":"publisher","first-page":"7","DOI":"10.4103\/ijt.ijt_93_16","volume":"9","author":"R Aswini","year":"2017","unstructured":"Aswini R, Jayapalan S. Modified Ferriman-Gallwey score in hirsutism and its association with metabolic syndrome. Int J Trichology. 2017;9(1):7\u201313. https:\/\/doi.org\/10.4103\/ijt.ijt_93_16.","journal-title":"Int J Trichology"},{"issue":"5","key":"9534_CR44","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1111\/j.1464-5491.2006.01858.x","volume":"23","author":"KG Alberti","year":"2006","unstructured":"Alberti KG, Zimmet P, Shaw J. The metabolic syndrome - a new worldwide definition. A consensus statement from the International Diabetes Federation. Diabetes Med. 2006;23(5):469\u201380. https:\/\/doi.org\/10.1111\/j.1464-5491.2006.01858.x.","journal-title":"Diabetes Med"},{"key":"9534_CR45","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1053\/gast.2002.35354","volume":"123","author":"S Saadeh","year":"2002","unstructured":"Saadeh S, Younossi ZM, Remer EM, et al. The utility of radiological imaging in non alcoholic fatty liver disease. Gastroenterology. 2002;123:745\u201350. https:\/\/doi.org\/10.1053\/gast.2002.35354.","journal-title":"Gastroenterology"},{"key":"9534_CR46","doi-asserted-by":"publisher","DOI":"10.1177\/2055102918788195","author":"S Williams","year":"2018","unstructured":"Williams S, Sheffield D, Knibb R. The Polycystic Ovary Syndrome Quality of Life scale (PCOSQOL): development and preliminary validation. Health Psychol Open. 2018. https:\/\/doi.org\/10.1177\/2055102918788195.","journal-title":"Health Psychol Open"},{"issue":"2","key":"9534_CR47","doi-asserted-by":"publisher","first-page":"96","DOI":"10.4103\/jhrs.jhrs_84_25","volume":"18","author":"R Mahey","year":"2025","unstructured":"Mahey R, Satapathy S, Haldar P, Kumari S, Gupta M, Jayraj AK, et al. Translation, cross-cultural adaptation and validation of Hindi version of Polycystic Ovary Syndrome-quality of Life Scale (PCOSQOL-I) - a cross-sectional study. J Hum Reprod Sci. 2025;18(2):96\u2013104. https:\/\/doi.org\/10.4103\/jhrs.jhrs_84_25.","journal-title":"J Hum Reprod Sci"},{"key":"9534_CR48","unstructured":"Committee for Medicinal Products for Human Use (CHMP). CPMP\/ICH\/363\/96. ICH E9 statistical principles for clinical trials. 1998. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-e-9-statistical-principles-clinical-trials-step-5_en.pdf"},{"key":"9534_CR49","unstructured":"Committee for Medicinal Products for Human Use (CHMP). EMA\/CHMP\/ICH\/436221\/2017 ICH E9 (R1) addendum on estimands and sensitivity analysis in clinical trials to the guideline on statistical principles for clinical trials. 2020. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-e9-r1-addendum-estimands-sensitivity-analysis-clinical-trials-guideline-statistical-principles_en.pdf."},{"key":"9534_CR50","unstructured":"Adult BMI categories. Available at https:\/\/www.cdc.gov\/bmi\/adult-calculator\/bmi-categories.html (Accessed on 11.11.24)."}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-026-09534-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-026-09534-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-026-09534-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T01:40:57Z","timestamp":1786930857000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13063-026-09534-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9534"],"URL":"https:\/\/doi.org\/10.1186\/s13063-026-09534-5","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,11]]},"assertion":[{"value":"16 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study is approved by the by Biomedical Research Ethics Committee of our institute vide letter no. BREC\/25\/278 dated 09.09.2025 in accordance with the ethical standards defined under Declaration of Helsinki and New Drugs and Clinical Trials Rules, 2019. Written informed consent will be obtained from all the participants before their inclusion in the study. The participants will be provided with detailed information regarding the purpose, procedures, potential risks, and benefits of the study, and their voluntary participation and right to withdraw at any time will be emphasized.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"532"}}